150736-72-4

Basic information

• Product Name: N-BOC-(S)-2-AMINO-1-BUTANOL, 96%
• Synonyms: Carbamic acid, [(1S)-1-(hydroxymethyl)propyl]-, 1,1-dimethylethyl ester (9CI);(S)-tert-butyl 1-hydroxybutan-2-ylcarbaMate;CarbaMic acid, N-[(1S)-1-(hydroxyMethyl)propyl]-, 1,1-diMethylethyl ester;Boc-2-Abu-ol
• CAS NO: 150736-72-4
• Molecular Formula: C₉H₁₉NO₃
• Molecular Weight: 189.25206
• Product Categories: N-BOC;Amino Alcohols;Chiral Building Blocks;Organic Building Blocks
• Mol File: 150736-72-4.mol

Chemical Properties

• Melting Point: 40-45 °C
• Boiling Point: 292.9oC at 760 mmHg
• Flash Point: 110 °C
• Appearance: /
• Density: 1.01g/cm3
• Vapor Pressure: 0.000189mmHg at 25°C
• Refractive Index: 1.452
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: N-BOC-(S)-2-AMINO-1-BUTANOL, 96%(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-(S)-2-AMINO-1-BUTANOL, 96%(150736-72-4)
• EPA Substance Registry System: N-BOC-(S)-2-AMINO-1-BUTANOL, 96%(150736-72-4)

Safety Data

• Hazard Codes: C
• Statements: 22-34
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 2923 8/PG 3
• WGK Germany: 1
• Hazardous Substances Data: 150736-72-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Manufacturing:
N-BOC-(S)-2-AMINO-1-BUTANOL, 96% is used as a building block for developing bioactive small molecules, contributing to the creation of new pharmaceutical compounds.
Used in Chemical Synthesis:
N-BOC-(S)-2-AMINO-1-BUTANOL, 96% is used as a protected amino alcohol for the synthesis of various organic compounds, where the BOC group serves to control the reactivity of the molecule during the synthesis process.
Used in Chemical Analysis:
N-BOC-(S)-2-AMINO-1-BUTANOL, 96% is used as a reference compound or in the preparation of standards for enantiomeric analysis, taking advantage of its chiral center for studying the properties of enantiomers.
Used in Biochemical Research:
N-BOC-(S)-2-AMINO-1-BUTANOL, 96% is used as a reagent in biochemical studies, where its protected form allows for controlled reactions and the investigation of molecular interactions.

InChI:InChI=1/C9H19NO3/c1-5-7(6-11)10-8(12)13-9(2,3)4/h7,11H,5-6H2,1-4H3,(H,10,12)/t7-/m0/s1

Upstream product

• 5856-62-2 (S)-2-aminobutan-1-ol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 251325-57-2 (1-hydroxymethyl-propenyl)-carbamic acid tert-butyl ester 
• 34306-42-8 Boc-Abu 
• 63658-16-2 (Z)-methyl 2-((tertbutoxycarbonyl)amino)but-2-enoate 
• 34619-03-9 tert-butyldicarbonate 
• 121056-95-9 trimethyl 2-(tert-butoxycarbonylamino)phosphonoacetate 

Downstream Products

• 1025065-72-8 (S)-2-(3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-ylamino)butan-1-ol 
• 1025066-20-9 C₂₂H₂₅F₃N₄O₄ 
• 13896-06-5 (S)-(-)-4-ethyl-2-oxazolidinone 
• 1598438-43-7 C₁₆H₂₃NO₄S 
• 251325-89-0 (S)-tert-butyl (1-aminobutan-2-yl)carbamate 
• 1297540-14-7 (S)-4-(1-(2-aminobutyl)-1H-pyrazol-3-yl)-2-chlorobenzonitrile 
• 153371-25-6 (2S)-2-(tert-butoxycarbonyl)aminobutyraldehyde 
• 153371-26-7 (S)-2-(N-t-butoxycarbonylamino)-butyl cyanide 
• 757976-46-8 tert-butyl [(1S)-1-({[4-(benzyloxy)phenyl]amino}methyl)propyl]carbamate 
• 757976-19-5 tert-butyl ((1S)-1-{[(4-methoxyphenyl)amino]methyl}propyl)carbamate 
• 882296-91-5 (1-{[(4-benzyloxy-phenyl)-(2-nitro-benzenesulfonyl)-amino]-methyl}-propyl)-carbamic acid tert-butyl ester 
• 911717-64-1 (1-{[(4-methoxy-phenyl)-(2-nitro-benzenesulfonyl)-amino]-methyl}-propyl)-carbamic acid tert-butyl ester 
• 352704-76-8 (S)-N-Boc-2-aminobutanol tosylate 

Relevant articles and documents

Design, synthesis, and structure-activity relationship studies of L-amino alcohol derivatives as broad-spectrum antifungal agents

To discover broad spectrum antifungal agents, two strategies were applied, and a novel class of L-amino alcohol derivatives were designed and synthesized. 3-F substituted compounds 14i, 14n, 14s and 14v exhibited excellent antifungal activities with broad antifungal spectra against C. albicans and C. tropicalis, with MIC values in the range of 0.03–0.06 μg/mL, and against A. fumigatus and C. neoformans, with MIC values in the range of 1–2 μg/mL. Notably, Compounds 14i, 14n, 14s and 14v also displayed moderate activities against fluconazole-resistance strains 17# and CaR that were isolated from AIDS patients. Moreover, only compounds in the S-configuration showed antifungal activity. Preliminary mechanistic studies showed that the potent antifungal activity of compound 14v stemmed from inhibition of C. albicans CYP51. Compounds 14n and 14v were almost nontoxic to mammalian A549 cells, and their stability in human plasma was excellent.

Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor

Inhibition of mutant IDH1 is being evaluated clinically as a promising treatment option for various cancers with hotspot mutation at Arg132. Having identified an allosteric, induced pocket of IDH1R132H, we have explored 3-pyrimidin-4-yl-oxazolidin-2-ones as mutant IDH1 inhibitors for in vivo modulation of 2-HG production and potential brain penetration. We report here optimization efforts toward the identification of clinical candidate IDH305 (13), a potent and selective mutant IDH1 inhibitor that has demonstrated brain exposure in rodents. Preclinical characterization of this compound exhibited in vivo correlation of 2-HG reduction and efficacy in a patient-derived IDH1 mutant xenograft tumor model. IDH305 (13) has progressed into human clinical trials for the treatment of cancers with IDH1 mutation.

NOVEL PYRROLIDINE DERIVATIVES

The invention relates to a compound of formula (I) wherein A and R1 to R7 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Synthesis of proline analogues as potent and selective cathepsin S inhibitors

Cathepsin S is a potential target of autoimmune disease. A series of proline derived compounds were synthesized and evaluated as cathepsin S inhibitors. We discovered potent cathepsin S inhibitors through structure-activity relationship studies of proline analogues. In particular, compound 19-(S) showed promising in vitro/vivo pharmacological activities and properties as a selective cathepsin S inhibitor.

NOVEL PYRROLIDINE DERIVATIVES AS INHIBITORS OF CATHEPSIN

The invention relates to a compound of formula (I), wherein A and R1 to R7 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 2: α-Branched quaternary amines

We report the synthesis and biological evaluation of a series of novel α-branched pyrazinoyl quaternary amines for their ability to block ion transport via the epithelial sodium channel (ENaC) in human bronchial epithelial cells (HBECs). Compound 12g has an IC50 of 30 nM and is highly efficacious in the Guinea-pig tracheal potential difference (TPD) model of ENaC blockade with an ED50 of 1 μg kg-1 at 1 h. In addition the SAR results demonstrate for the first time the chiral nature of the binding site of human ENaC. As such, pyrazinoyl quaternary amines represent a promising new class of ENaC blockers for the treatment of cystic fibrosis that are structurally distinct from the pyrazinoyl guanidine chemotype found in prototypical ENaC blockers such as amiloride.

Synthesis of imidacloprid derivatives with a chiral alkylated imidazolidine ring and evaluation of their insecticidal activity and affinity to the nicotinic acetylcholine receptor

A series of imidacloprid (IMI) derivatives with an alkylated imidazolidine ring were asymmetrically synthesized to evaluate their insecticidal activity against adult female housefly, Musca domestica, and affinity to the nicotinic acetylcholine receptor of the flies. The bulkier the alkyl group, the lower was the receptor affinity, but the derivatives methylated and ethylated at the R-5-position of the imidazolidine ring were equipotent to the unsubstituted compound. Quantitative structure-activity relationship (QSAR) analysis of the receptor affinity demonstrated that the introduction of a substituent into the imidazolidine ring was fundamentally disadvantageous, but the introduction of a substituent at the R-5-position was permissible in the case of its small size. The binding model of the synthesized derivatives with the receptor supported the QSAR analysis, indicating the existence of space for a short alkyl group around the R-5-position in the ligand-binding site. In addition, positive correlation was observed between the insecticidal activity and receptor affinity, suggesting that the receptor affinity was the primary factor in influencing the insecticidal activity even if the imidazolidine ring was modified.

COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC.

The invention provides a novel class of compounds viz. generally lipopeptides like Pam3CSK4, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness a vaccine.

COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cathepsin S.